Expression of Vascular Endothelial Growth Factor Family Members in Head and Neck Squamous Cell Carcinoma Correlates with Lymph Node Metastasis
Overview
Authors
Affiliations
Background: The expression of vascular endothelial growth factor (VEGF)-A isoforms (121, 165, 189, 206), VEGF-B, VEGF-C and VEGF-D in both experimental and clinical models of head and neck squamous cell carcinoma (HNSCC) was determined and correlated with conventional clinicopathologic parameters, with particular reference to cervical nodal metastasis.
Methods: The mRNA expression of VEGFs in 14 HNSCC cell lines was compared with 4 normal keratinocyte cultures and 10 fibroblast cultures using a semiquantitative reverse transcription polymerase chain reaction (RT-PCR) assay. Protein levels were determined by Western blotting and enzyme-linked immunosorbent assay (ELISA). The authors then examined the expression of VEGFs in tissues from 54 patients including histologically normal epithelium (n = 32), early invasive squamous cell carcinomas (SCCs) (n = 23), advanced primary SCCs (n = 31), and lymph node metastases (n = 27).
Results: Increased levels of VEGF-A (all four isoforms) and VEGF-C were found in tumor cell lines compared with normal cells, whereas no differences in VEGF-B levels were found. VEGF-D expression, however, was lower in HNSCC cells. Studies in clinical samples showed highly significant increases in mRNA expression of all four isoforms of VEGF-A and VEGF-C in tumors versus normal epithelium. In contrast, the levels of VEGF-D were significantly decreased in tumors, and VEGF-B expression appeared similar in both normal and malignant tissues. Multivariate analysis demonstrated that an infiltrative mode of invasion and enhanced expression of VEGF-A (isoforms 121 and 165) and VEGF-C had predictive value for the presence of cervical nodal metastases.
Conclusions: Up-regulation of VEGF-A (two isoforms) and VEGF-C and down-regulation of VEGF-D have been common features in HNSCC. Thus VEGF-A and VEGF-C appeared to play a vital role in the metastatic process of HNSCC.
Garcia-Perez O, Melgar-Vilaplana L, Sifaoui I, Smietanska A, Cordoba-Lanus E, Fernandez-de-Misa R Int J Mol Sci. 2024; 25(1).
PMID: 38203550 PMC: 10779353. DOI: 10.3390/ijms25010379.
Tzuri N, Yegodayev K, Novoplansky O, Elkabets M, Aharoni A, Papo N Sci Rep. 2023; 13(1):11923.
PMID: 37488176 PMC: 10366146. DOI: 10.1038/s41598-023-39076-8.
Combination Therapy as a Promising Way to Fight Oral Cancer.
Silva J, Pinto B, Monteiro L, Silva P, Bousbaa H Pharmaceutics. 2023; 15(6).
PMID: 37376101 PMC: 10301495. DOI: 10.3390/pharmaceutics15061653.
Itashiki Y, Harada K, Takenawa T, Ferdous T, Ueyama Y, Mishima K Oncol Lett. 2021; 22(4):730.
PMID: 34429770 PMC: 8371954. DOI: 10.3892/ol.2021.12991.
Shi L, Lv R, Li C, Han D, Ren Z, Ren G Transl Androl Urol. 2020; 9(4):1670-1677.
PMID: 32944528 PMC: 7475675. DOI: 10.21037/tau-20-970.